Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kate Young

Sleep Medicine Elizabethtown, KY Medical Doctor

NPI 1184291585 CMS profile 9188220

2409 Ring Rd Ste 106, Elizabethtown, KY 42701

Open in the dashboard

General payments

$3,513

35 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kate Young of Elizabethtown, KY is reported in the CMS Open Payments database as having received $3,513 across 35 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Sleep Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,592 24
2024 General $889 9
2023 General $14 1
2022 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kate Young
  • Sleep Medicine median
  • Middle half of Sleep Medicine
  • National median

In program year 2025, general payments to Kate Young were reported at $2,592. Among 184 Sleep Medicine profiles paid that year, the median was $557 and the middle half received between $150 and $1,388.

Show as a table
Year Kate Young Sleep Medicine median Middle half National median
2019 $0 $170 $52–$432 $163
2020 $0 $103 $25–$262 $114
2021 $0 $160 $67–$690 $132
2022 $17 $217 $54–$1,038 $149
2023 $14 $301 $125–$877 $160
2024 $889 $333 $95–$956 $164
2025 $2,592 $557 $150–$1,388 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Noctrix Health, Inc. $1,452 1 payment
  2. Inspire Medical Systems, Inc. $1,147 4 payments
  3. Harmony Biosciences LLC $504 12 payments
  4. Jazz Pharmaceuticals Inc. $280 11 payments
  5. Axsome Therapeutics, Inc. $68 3 payments
  6. Lilly USA, LLC $33 2 payments
  7. Fisher & Paykel Healthcare Inc $14 1 payment
  8. Exact Sciences Corporation $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,457 29 payments
  2. Travel and Lodging $750 2 payments
  3. Education $305 4 payments
Products named General payments · program years 2022–2025
  1. NIDRA $1,452 1 payment
  2. INSPIRE $1,147 4 payments
  3. WAKIX Narcolepsy $303 8 payments
  4. XYWAV $190 10 payments
  5. WAKIX Narcoplepsy $131 3 payments
  6. XYREM $90 1 payment
  7. Sunosi $68 3 payments
  8. MOUNJARO $33 2 payments
  9. TRULICITY $17 1 payment
  10. FISHER & PAYKEL HEALTHCARE $14 1 payment
  11. Other $71 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

383

Median for Family Medicine: 130

Drug cost

$16,131

Median for Family Medicine: $5,773

Branded share of claims

5.7%

Median for Family Medicine: 16%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Spiriva Handihaler Tiotropium Bromide Brand 11 $6,396
Eliquis Apixaban Brand 11 $6,261
Atorvastatin Calcium Generic 52 $554
Fluticasone Propionate Generic 25 $422
Losartan Potassium Generic 32 $366
Spironolactone Generic 28 $317
Amlodipine Besylate Generic 55 $278
Promethazine Hcl Generic 13 $269
Levothyroxine Sodium Generic 36 $257
Pravastatin Sodium Generic 14 $208

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 699 Part D prescribers listed as Family Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAKIX
  • Harmony Biosciences LLC $131
$131 — —
XYREM
  • JAZZ PHARMACEUTICALS INC. $90
$90 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $39
$39 — —
MOUNJARO
  • Lilly USA, LLC $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

35 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sleep Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record